Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812)

Antiviral Research

Volumn 60, Issue 1, 2003, Pages 17-25

  Sidwell, R W ^a   Bailey, K W ^a   Morrey, J D ^a   Wong, M H ^a   Baldwin, T J ^a   Smee, D F ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral; BCX 1812; Immunosuppression; Influenza virus; Neuraminidase inhibitor; Peramivir; RWJ 270201

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PERAMIVIR; SIALIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEATH; EXPOSURE; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA VIRUS; INHIBITION KINETICS; MOUSE; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; PROVOCATION TEST; SCID MOUSE; VIRUS TITRATION;

INFLUENZA A VIRUS; INFLUENZA VIRUS;

EID: 0141567636     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(03)00113-X     Document Type: Article

References (22)

1. Anonymous, 2002. BioCryst influenza drug fails in phase III trial; development halted. Antivir. Agents Bull. 15, 162-163.
2. Bantia S., Parker C.D., Ananth S.L., Horn L.L., Andries K., Chand P., Kotian P.L., Dehghani A., El-Kattan Y., Lin T., Hutchinson T.L., Montgomery J.A., Kellog D.L., Babu Y.S. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:2001;1162-1167.
3. Berd, D., Maguire Jr., H.C., Mastrangelo, M.J., 1984. Immunopotentiation by cyclophosphamide and other cytotoxic agents. In: Fenichel, R.L., Chirigos, M.A. (Eds.), Immune Modulation Agents and Their Mechanisms. Marcel Dekker, New York, pp. 39-61.
4. Hayden, F., Treanor, J., Qu, R., Fowler, C., 2000. Safety and efficacy of an oral neuraminidase inhibitor RWJ-270201 in treating experimental influenza A and B in healthy adult volunteers. In: Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000. Abstracts, No. 1156.
5. Hers J.F.P., Mulder J., Masure I.N., Kuip V. Studies on the pathogenesis of influenza virus pneumonia in mice. J. Pathol. Bacteriol. 83:1962;207-217.
6. Laughlin C.A., Black R.J., Feinbert J., Freeman D.J., Ramsey J., Ussery M.A., Whitley R.J. Resistance to antiviral drugs. ASM News. 57:1991;514-517.
7. Leung K.N., Ata G.L. Cells mediating delayed-type hypersensitivity in the lungs of mice infected with an influenza A virus. Scand. J. Immunol. 12:1980;393-400.
8. Ljungman P., Andersson J., Aschan J., Barkholt L., Ehrnst A., Johansson M., Weiland O. Influenza A in immunocompromised patients. Clin. Infect. Dis. 17:1993;244-247.
9. Raut S., Hurd J., Blandford G., Heath R.B., Cureton R.J. The pathogenesis of infections of the mouse caused by virulent and avirulent variants of an influenza virus. J. Med. Microbiol. 8:1975;127-156.
10. Rocha E., Cox N.J., Black R.A., Harmon M.W., Harrison C.J., Kendal A.P. Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child. J. Virol. 65:1991;2340-2350.
11. Schultz L.D., Sidman C.L. Genetically determined murine models of immunodeficiency. Annu. Rev. Immunol. 5:1987;367-403.
12. Selgrade M.K., Daniels M.J., Hu P.C., Miller F.J., Graham J.A. Effects of immunosuppression with cyclophosphamide on acute murine cytomegalovirus infection and virus-augmented natural killer cell activity. Infect. Immun. 38:1982;1046-1055.
13. Sidwell R.W., Huffman J.H., Gilbert J., Moscon B., Pedersen G.H., Burger R.A., Warren R.P. Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice. Antimicrob. Agents Chemother. 36:1992;473-476.
14. Sidwell R.W., Huffman J.H., Bailey K.W., Wong M.H., Nimrod A., Panet A. Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice. Antimicrob. Agents Chemother. 40:1996;2626-2631.
15. Sidwell R.W., Smee D.F., Huffman J.H., Barnard D.L., Bailey K.W., Morrey J.D., Babu Y.S. In vivo influenza-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201. Antimicrob. Agents Chemother. 45:2001a;749-757.
16. Sidwell R.W., Smee D.F., Huffman J.H., Barnard D.L., Morrey J.D., Bailey K.W., Feng W.-C., Babu Y.S., Bush K. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. Antivir. Res. 51:2001b;179-187.
17. Smee D.F., Burger R.A., Coombs J., Huffman J.H., Sidwell R.W. Progressive murine cytomegalovirus disease after termination of ganciclovir therapy in mice immunosuppressed by cyclophosphamide treatment. J. Infect. Dis. 164:1991;958-961.
18. Smee D.F., Burger R.A., Warren R.P., Bailey K.W., Sidwell R.W. An immunosuppressed mouse model of lethal murine gammaherpesvirus 68 infection for studying potential treatment of Epstein-Barr virus infection in man. Antivir. Chem. Chemother. 8:1997;573-581.
19. Smee D.F., Huffman J.H., Morrison A.C., Barnard D.L., Sidwell R.W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activity. Antimicrob. Agents Chemother. 45:2001;743-748.
20. Sweet C., Jakeman K.J., Bush K., Wagaman P.C., McKown L.A., Streeter A.J., Desai-Krieger D., Chand P., Babu Y.S. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob. Agents Chemother. 46:2002;996-1004.
21. Whimbey E., Bodey G.P. Viral pneumonia in the immunocompromised adult with neoplastic diseases: the role of common community respiratory viruses. Semin. Respir. Infect. 7:1992;122-131.
22. Wyde P.R., Couch R.B., Mackler B.F., Cate T.R., Levy B.M. Effects of low- and high-passage influenza virus infection in normal and nude mice. Infect. Immun. 15:1977;221-229.